## Suven Pharmaceuticals Limited (SUVENPHAR) Investment Report - December 20, 2024

**1. Company Overview:**

Suven Pharmaceuticals Limited (SUVENPHAR) operates in the Pharmaceuticals industry.  Listed on the NSE on March 9, 2020, the company's specific positioning within the sector requires further research beyond the provided data.  This report analyzes available data to provide investment recommendations.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | 1,178.90       | Closing price as of December 20, 2024                               |
| Percentage Change (PChange) | -3.09%         | Significant negative daily change                                       |
| Pre-Open Activity          | Mixed           | Pre-open orders show some buying interest but significant selling pressure at higher prices.  Final pre-open price was 1214.45, indicating a downward trend. |
| Week High                   | 1,360.00       | Indicates recent price volatility                                      |
| Week Low                    | 585.20         | Significant week-to-week price fluctuation, highlighting volatility     |
| VWAP                        | 1,195.41       | Volume Weighted Average Price suggests a slightly higher average trading price than the closing price. |
| Sector PE                   | 127.51         | High Price-to-Earnings ratio for the sector, indicating potentially high valuations. |
| Symbol PE                   | 127.51         | High Price-to-Earnings ratio for SUVENPHAR, mirroring the sector.     |
| Delivery Percentage         | 60.34%         | Relatively high delivery percentage suggests some degree of genuine investment interest. |
| Market Depth                | Low             | The provided order book data shows very low market depth, indicating limited liquidity.  This is a significant risk factor. |


**3. Financial Performance:**

The provided financial data shows a mixed picture. While revenue has generally increased over the past five quarters, profit after tax and EPS have fluctuated significantly.  The company has reported losses in the last four quarters.  Further analysis is needed to determine the underlying causes of these losses.  Key financial ratios (e.g., debt-to-equity, return on equity) are missing and would be crucial for a complete assessment.

| Quarter      | Revenue (₹ Cr) | Expenditure (₹ Cr) | Profit After Tax (₹ Cr) | EPS (₹) |
|--------------|-----------------|----------------------|--------------------------|---------|
| Q1 FY25 (Jul-Sep 2024) | 24.95           | 14.88                 | 7.63                     | 3.00    |
| Q4 FY24 (Apr-Jun 2024) | 24.00           | 15.27                 | 6.51                     | 2.56    |
| Q3 FY24 (Oct-Dec 2023) | 22.68           | 15.73                 | 5.24                     | 2.06    |
| Q2 FY24 (Jul-Sep 2023) | 23.88           | 13.83                 | 7.47                     | 2.94    |
| Q1 FY24 (Apr-Jun 2023) | 35.41           | 18.64                 | 12.43                    | 4.88    |


**4. Corporate Actions and Announcements:**

Recent announcements include several board meetings to discuss financial results and an acquisition.  The company has also declared several interim and special dividends in the past.  The lack of details on the acquisition and its potential impact on the stock price is a limitation.  The upcoming Annual General Meeting (AGM) is a relevant event to monitor.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 60.00                        | 40.00      | 0.00                | 100.00    |
| 31-Dec-2023  | 60.00                        | 40.00      | 0.00                | 100.00    |
| 31-Mar-2024  | 50.10                        | 49.90      | 0.00                | 100.00    |
| 30-Jun-2024  | 50.10                        | 49.90      | 0.00                | 100.00    |
| 30-Sep-2024  | 50.10                        | 49.90      | 0.00                | 100.00    |

A significant change in promoter shareholding occurred between December 2023 and March 2024, dropping from 60% to 50.10%.  This change needs further investigation to understand its implications.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the week's high and low prices and the significant daily price swings.  The low market depth further exacerbates the risk.  The risk-reward profile is currently unfavorable due to the high volatility and the recent financial performance.

**7. Advantages of Buying the Stock:**

* Consistent revenue growth (although profitability is questionable).
* History of dividend payments.

**8. Disadvantages and Risks:**

* High volatility and low liquidity.
* Recent losses and fluctuating profitability.
* High PE ratio compared to the sector.
* Uncertainty surrounding the impact of recent acquisitions and changes in shareholding.
* Lack of crucial financial ratios for a comprehensive analysis.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The high volatility and low liquidity make short-term trading extremely risky.  The negative price momentum further strengthens this recommendation.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends heavily on the success of recent acquisitions and the company's ability to improve profitability.  Further investigation into the financial statements and the nature of the acquisitions is needed.  Given the current uncertainty, buying is not recommended.

* **Long-term (1 year and beyond): Don't Buy.**  While the company shows some revenue growth, the consistent losses and high volatility make it a risky long-term investment without significant improvement in fundamentals.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 4.5**

* Financial health: 3/10 (Consistent losses and lack of key ratios)
* Market performance: 2/10 (High volatility, negative price momentum, low liquidity)
* Volatility and risk: 2/10 (High volatility, low liquidity)
* Corporate actions and governance: 6/10 (Dividend history, but acquisition details are lacking)
* Shareholding patterns: 5/10 (Significant change in promoter shareholding requires further investigation)

**Analysis Score (out of 10): 7**

* Completeness and utilization of data: 8/10 (Most data points were used, but some crucial information was missing)
* Accuracy and clarity of analysis: 7/10 (Analysis is clear, but conclusions are limited by missing data)
* Professional formatting: 8/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data, SUVENPHAR presents a high-risk, low-reward profile.  The high volatility, low liquidity, and recent financial losses outweigh the advantages of dividend payments and revenue growth.  A "Don't Buy" recommendation is given for both short-term and long-term investment horizons.  A "Hold" recommendation is given for medium-term only if the investor already holds the stock, pending further investigation into the company's financial health and the impact of recent corporate actions.  Further research is strongly recommended before making any investment decisions.  Accessing the XBRL and NA attachments linked in the financial results data would provide a more comprehensive analysis.
